文献速递白内障与屈光手术眼底病与葡萄膜炎

二甲双胍对早期Nd:YAG激光后囊切开术的保护作用

The Protective Effect of Metformin Use on Early Nd:YAG Laser Capsulotomy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2021-01-01

本研究通过回顾性队列(9798眼)和实验室实验,探讨二甲双胍对后囊膜混浊(PCO)导致早期Nd:YAG激光治疗的影响及分子机制。多变量分析显示,仅糖尿病患者中使用二甲双胍者显著降低Nd:YAG风险(HR 0.68,95%CI 0.54-0.85,P=0.0008),而不用二甲双胍的糖尿病患者无显著差异。实验室表明二甲双胍可下调晶状体上皮细胞上皮-间质转化(EMT)标志物。

要点

  • 二甲双胍使用与糖尿病患者早期Nd:YAG激光后囊切开风险降低独立相关。
  • 糖尿病患者未用二甲双胍者风险与无糖尿病者无显著差异。
  • 二甲双胍可抑制TGF-β2诱导的晶状体上皮细胞EMT标志物表达。

核心结论

  • 二甲双胍对早期Nd:YAG激光后囊切开术的保护作用可能与其下调残余晶状体上皮细胞EMT有关。

研究设计与样本

  • 回顾性队列研究纳入9798只行超声乳化术的眼,采用群体平均Cox比例风险模型估计Nd:YAG风险。
  • 实验室研究检测二甲双胍对晶状体上皮细胞EMT标志物的影响,包括组织培养和小鼠晶状体囊外摘除模型。

主要发现

  • 9798眼中Nd:YAG激光后囊切开率为13.1%。
  • 单变量分析中二甲双胍使用和糖尿病均为Nd:YAG的保护因素。
  • 多变量分析以非糖尿病者为参照,仅糖尿病患者中使用二甲双胍显著保护(HR 0.68,95%CI 0.54-0.85,P=0.0008),不用二甲双胍的糖尿病患者无显著差异(P=0.5026)。
  • 二甲双胍降低TGF-β2诱导的晶状体上皮细胞α-SMA和pERK水平。
  • 小鼠晶状体囊外摘除后二甲双胍减少晶状体上皮细胞α-SMA表达。

关键数值与推荐

  • 多变量分析中糖尿病患者使用二甲双胍的Nd:YAG风险比为0.68(95%CI 0.54-0.85,P=0.0008)。
  • 不用二甲双胍的糖尿病患者与参照组比较P=0.5026。

临床怎么用

  • 糖尿病患者使用二甲双胍可能与降低早期Nd:YAG激光后囊切开风险相关。
  • 二甲双胍可能通过抑制晶状体上皮细胞EMT来预防PCO。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the effect of metformin on early Nd:YAG laser treatment for posterior capsule opacification (PCO) and to explore a molecular mechanism to explain a possible protective effect of metformin against PCO. METHODS: We conducted: 1) a retrospective cohort study of patient eyes undergoing phacoemulsification at our institution; and 2) laboratory investigation of the effect of metformin on the behavior of lens epithelial cells in the context of an animal model for PCO. Population-averaged Cox proportional hazards modeling was used to estimate risk for time to Nd:YAG. For laboratory studies, expression of markers for epithelial-to-mesenchymal transition (EMT) implicated in PCO pathogenesis was measured in tissue culture and following extracapsular lens extraction in a mouse model. RESULTS: The rate of Nd:YAG laser capsulotomy was 13.1% among the 9798 eyes. Both metformin use and diabetes were protective factors for Nd:YAG laser capsulotomy in univariate analysis. However, in multivariable analysis with nondiabetics as the reference group, only metformin use among diabetics was significantly protective of Nd:YAG (hazard ratio: 0.68, 95% CI: 0.54-0.85, P = 0.0008), while eyes of patients with diabetes without metformin use did not significantly differ (P = 0.5026). Treatment of lens epithelial cells with metformin reduced the level of the EMT markers ⍺-SMA and pERK induced by TGF-β2. Similarly, metformin treatment reduced ⍺-SMA expression in lens epithelial cells following extracapsular lens extraction in a mouse model. CONCLUSIONS: The protective effect of metformin against early Nd:YAG may relate to its ability to downregulate EMT in residual lens epithelial cells that otherwise trend toward myofibroblast development and PCO.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Patnaik JL, Christopher KL, Pedler MG, et al. The Protective Effect of Metformin Use on Early Nd:YAG Laser Capsulotomy. Invest Ophthalmol Vis Sci. 2021. PMID: 34415985. doi:10.1167/iovs.62.10.24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。